Ceralasertib + Olaparib + Durvalumab
Phase 2RecruitingDevelopment Stage
Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
Jan 17, 2019 → Mar 31, 2028
About Ceralasertib + Olaparib + Durvalumab
Ceralasertib + Olaparib + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Clear Cell Renal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03682289. Target conditions include Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm.
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04065269 | Phase 2 | Active |
| NCT03682289 | Phase 2 | Recruiting |
Competing Products
20 competing products in Clear Cell Renal Cell Carcinoma